
Creative Medical Technology Holdings Inc (NASDAQ:CELZ) shares are trading higher Wednesday after the company announced top-line results for its follow-up StemSpine pilot study.
The initial study showed significant efficacy of the StemSpine procedure for treating chronic lower back pain without any serious adverse effects.